Defining the therapeutic algorithm in patients with HR positive breast cancer - United States

Target Audience
The initiative will target oncology clinicians in the US, Germany, Spain, Italy, and France, and specifically those actively involved in the treatment of breast cancer

Learning Objectives
Upon completion of this activity, participants should be better able to:

Assess the efficacy of new target therapy options in the management of patients with HR + early and metastatic BC with and implications for team-based and shared decision-making globall
Apply the most recent evidence-based recommendations when managing patients with HR+ and BRCAm+ BC, based on specific patient and tumor characteristics
Discuss the most recent evidence -based recommendations, guidelines, and clinical trial presentations on the role of antibody-drug conjugates on the management of patients with HER2+, HER2-Low, and TNBC